Description: Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices in the ophthalmic field worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device, a home-based and patient self-monitoring optical coherence tomography devices to treat wet age-related macular degeneration and diabetic macular edema, which brings retinal edema and reduction in visual acuity; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
Home Page: www.kubotaholdings.co.jp
Kasumigaseki Tokyu Building
Tokyo,
100-0013
Japan
Phone:
81 3 6550 8928
Officers
| Name | Title |
|---|---|
| Dr. Ryo Kubota | Founder, Chairman, Chief Exec. Officer, Pres and Representative Exec. Officer |
| Tomomi Sukagawa | Director of Investor Relations & Communication |
| Mr. Edward H. Danse MBA | Chief Bus. Officer of Acucela Inc |
| Dr. Lukas Scheibler M.D., Ph.D. | Exec. VP of R&D - Acucela Inc |
Exchange: OTCGREY
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 11.9234 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |